Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
  • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
  • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
  • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
  • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/56—Nitrogen atoms
  • C07D211/58—Nitrogen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/70—Sulfur atoms
  • C07D213/71—Sulfur atoms to which a second hetero atom is attached
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Definitions

• the present invention relates to new D 3 dopamine receptor subtype selective ligands of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof which are useful in the therapy and/or prevention of psychoses (e.g. schizophrenia, schizo-affective disorders, etc.) and other central nervous system and ophthalmological disorders.
• the present invention also relates to the processes for producing compounds of formula (I) and to pharmacological compositions containing the same.
• PCT Patent Publication WO 98/50364 describes tetrahydroisoquinoline derivatives which have affinity for dopamine receptors and useful as antipsychotic agents.
• PCT Patent Publication WO 97/45403 discloses aryl substituted cyclic amines as selective dopamine D 3 ligands.
• German Patent Publication DE 19728996 describes triazol derivatives.
• the compounds are said to be dopamine D 3 receptor antagonists and/or agonists useful for the treatment of central nervous system disorders e.g. Parkinson's disease or schizophrenia.
• central nervous system disorders e.g. Parkinson's disease or schizophrenia.
• the compounds mentioned in the above publications have affinity for dopamine D 3 receptors, their chemical structures differ from the structure of compounds of the present invention.
• the present invention relates to new D 3 dopamine receptor subtype selective ligands having sulfonamide structures of formula (I)
• - X represents a nitrogen atom or CH group
• - Y represents a bond when X stands for nitrogen, or an oxygen atom or NH or CH 2 or OCH group when X stands for CH group;
• R-i, Pi 2 , P» 3 may be the same or different and represent independently a substituent selected from hydrogen, halogen, C- ⁇ - 6 -alkyl, C 1-6 alkoxy, cyano, hydroxy, trifluoromethyl, C ⁇ -6 -alkylsulfonyloxy, trifluoromethanesulfonyloxy, C ⁇ - 6 -alkanoyloxy, amino, alkylamino, alkanoylamino, alkylsulfonylamino, arylsulfonylamino, aminocarbonyl, carboxy, N-hydroxycarmamimidoyl, carbamimidoyl, hydroxycarbamoyl, thiocarbamoyl, sulfamoyl, mono or bicyclic heterocyclic group or optionally substituted phenyl, or two adjacent groups of R-i, R 2 and R 3 may combine to form an optionally substituted fused mono or bicyclic heterocyclic group
• - Q represents an optionally substituted alkyl, aryl, aralkyl or heteroaralkyl group and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to the pharmacological compositions containing the same and their use in therapy and/or prevention of psychoses (e.g. schizophrenia, schizo-affective disorders, etc.), drug (e.g. alcohol, cocaine and nicotine, opioids etc.) abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, amnesia, eating disorders (e.g.
• psychoses e.g. schizophrenia, schizo-affective disorders, etc.
• drug e.g. alcohol, cocaine and nicotine, opioids etc.
• cognitive impairment accompanying schizophrenia mild-to-moderate cognitive deficits
• amnesia e.g.
• bulimia nervosa etc.
• attention deficit disorders hyperactivity disorders in children, psychotic depression, mania, paranoid and delusional disorders, dyskinetic disorders (e.g. Parkinson's disease, neuroleptic induced Parkinsonism, tardive dyskinesias) anxiety, sexual dysfunction, sleep disorders, emesis, aggression, autism, pain, ophthalmological diseases (e.g. glaucoma etc.).
• dyskinetic disorders e.g. Parkinson's disease, neuroleptic induced Parkinsonism, tardive dyskinesias
• anxiety sexual dysfunction
• sleep disorders emesis
• aggression aggression
• autism pain
• ophthalmological diseases e.g. glaucoma etc.
• the present invention relates to new compounds of formula (I)
• - X represents a nitrogen atom or CH group
• - Y represents a bond when X stands for nitrogen, or an oxygen atom or NH or CH 2 or OCH 2 group when X stands for CH group;
• R ⁇ , R 2 , R3 may be the same or different and represent independently a substituent selected from hydrogen, halogen, C ⁇ -6 -alkyl, d- 6 alkoxy, cyano, hydroxy, trifluoromethyl, d- ⁇ -alkylsulfonyloxy, trifluoromethanesulfonyloxy, C ⁇ .
• - Q represents an optionally substituted C-i-e-alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl group and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof.
• the aryl moiety may be selected from an optionally substituted mono- or bicyclic aryl namely phenyl or naphthyl group.
• a heteroaryl ring in the meaning of Q may be monocyclic or bicyclic ring.
• the monocyclic heteroaryl ring may be an optionally substituted 5- or 6- membered aromatic heterocyclic group containing 1 to 4 heteroatoms selected from O, N or S.
• Examples of 5- and 6-membered heterocyclic groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, isothiazolyl, isoxazolyl, pyrazinyl and pyrazolyl, preferably pyridyl and thienyl.
• bicyclic heteroaromatic groups include indazolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, quinoxolinyl, quinazolinyl, cinnolinyl or isoquinolinyl, preferably quinolinyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzimidazolyl and indolyl group.
• the substituents of substituted C ⁇ - 6 -alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl groups in the meaning of Q are selected from hydrogen, halogen, cyano, trifluoromethyl, d- ⁇ -alkyl, C ⁇ -6 -alkoxy, C ⁇ - 6 -alkanoyl, methylenedioxy, C 1-6 - alkylamino, d- ⁇ -alkanoylamino, optionally substituted aroyl, aryloxy, aminosulfonyl, arylsulfonylamido, optionally substituted mono or bicyclic aromatic or heteroaromatic ring, wherein the aryl may have the same meaning as mentioned above.
• the substituents of C ⁇ -6 -alkanoyloxy in the meaning of R ⁇ , R 2 and R 3 are selected from hydrogen or halogen.
• amino, aminoalkyl, aminocarbonyl, N-hydroxycarbamimidoyl, carbamimidoyl, hydroxycarbamoyl, thiocarbamoyl and sulfamoyl groups in the meaning of R-i, R 2 and R 3 may optionally be substituted on the N atom.
• the mono or bicyclic heterocyclic group in the meaning of R ⁇ , R 2 and R 3 may be saturated or unsaturated containing 1 to 4 heteroatoms selected from O, N or S.
• alkanoyl, alkanoylamino, alkanoyloxy groups may be straight or branched included methyl, ethyl, n-propyl, n-butyl, n-pentyl-, ti-hexyl and branched isomers thereof such as isopropyl, f-butyl, sec-butyl, and the like.
• the halogen substituent(s) in the compounds of formula (I) may be fluorine, chlorine, bromine or iodine, preferably fluorine, bromine and chlorine.
• the compounds of formula (I) can exist in the form of cis- and trans-isomers with respect to the configuration of the cyclohexane ring. These and their mixtures are likewise within the scope of the present invention. Preferably the compounds of the invention are in the trans configuration.
• the invention also relates to the salts of compounds of formula (I) formed with acids.
• Both organic and inorganic acids can be used for the formation of acid addition salts.
• Suitable inorganic acids can be for example hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid.
• Representatives of monovalent organic acids can be for example formic acid, acetic acid, propionic acid, and different butyric acids, valeric acids and capric acids.
• Representatives of bivalent organic acids can be for example oxalic acid, malonic acid, maleic acid, fumaric acid and succinic acid.
• organic acids can also be used, such as hydroxy acids for example citric acid, tartaric acid, or aromatic carboxylic acids for example benzoic acid or salicylic acid, as well as aliphatic and aromatic sulfonic acids for example methanesulfonic acid, naphtalenesulfonic acid and p-toluenesulfonic acid.
• hydroxy acids for example citric acid, tartaric acid, or aromatic carboxylic acids for example benzoic acid or salicylic acid
• aliphatic and aromatic sulfonic acids for example methanesulfonic acid, naphtalenesulfonic acid and p-toluenesulfonic acid.
• acid addition salts are pharmaceutically acceptable acid addition salts.
• the reason why acid addition salts, which do not belong to the pharmaceutically acceptable acid addition salts belong to the present invention is, that in given case they can be advantageous in the purification and/or isolation of the desired compounds.
• Solvates and hydrates of compounds of formula (I) are also included within the scope of the invention.
• the invention relates also to the salts of compounds of formula (I) formed with acids, especially the salts formed with pharmaceutically acceptable acids, the meaning of compound of formula (I) is either the free base or the salt even if it is not referred separately.
• Preferred compounds of the invention are those compounds of formula (I)
• - X represents a nitrogen atom or CH group
• - Y represents a bond when X stands for nitrogen, or an oxygen atom or NH or CH 2 or OCH 2 group when X stands for CH group;
• Ri R 2 , R 3 may be the same or different and represent independently hydrogen, alkyl, alkoxy, halogen, cyano, aminocarbonyl, trifluoromethyl, amino, alkylamino, alkanoylamino, alkylsulfonylamino, arylsulfonylamino, aminocarbonyl, carboxy, N-hydroxycarmamimidoyl, carbamimidoyl, hydroxycarbamoyl, thiocarbamoyl, sulfamoyl, mono or bicyclic heterocyclic group or optionally substituted phenyl, or two adjacent groups of Ri, R 2 and R 3 may combine to form an optionally substituted fused mono or bicyclic heterocyclic group;
• - Q represents dialkylamino, optionally substituted phenyl, biphenyl, pyridyl, thienyl, alkyl or quinolinyl; and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof.
• Especially preferred compounds of the invention are those compounds of formula (I)
• - X represents a nitrogen atom or CH group
• - Y represents a bond when X stands for nitrogen, or CH 2 group when X stands for CH group;
• R- R-i, R 2 , R3 may be the same or different and represent independently hydrogen, fluorine, bromine, chlorine atoms or cyano, trifluoromethyl, methyl, methoxy, ethoxy, aminocarbonyl, amino, alkylamino, alkanoylamino, alkylsulfonylamino, arylsulfonylamino, aminocarbonyl, carboxy, N-hydroxycarmamimidoyl, carbamimidoyl, hydroxycarbamoyl, thiocarbamoyl, sulfamoyl, mono or bicyclic heterocyclic group or optionally substituted phenyl, or two adjacent groups of Ri, R 2 and R 3 may combine to form an optionally substituted fused mono or bicyclic heterocyclic group;
• - Q represents C ⁇ - alkyl, dimethylamino, biphenyl, alkylphenyl, alkoxyphenyl, halophenyl, nitrophenyl, trifluoromethylphenyl or aminocarbonylmethylphenyl, pyridyl, or quinolinyl; and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof.
• subjects of the present invention are the synthesis of compounds of formula (I) and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the process of treatments and/or prevention with these compounds, which means administering to a mammal to be treated - including human - effective amount amounts of compounds of formula (I) of the present invention as such or as medicament.
• the present invention also provides processes for preparing compounds of formula (I) by forming a sulfonamide bond between a sulfochloride of formula (II) or a derivative thereof
• the sulfonamide bond formation may be carried out by known methods, preferably by reacting a sulfochloride of formula (II) with an amine of formula (III) in the presence of a base.
• the amine of formula (III) as a base or as a salt formed with an acid is dissolved in an appropriate solvent (for example chlorinated hydrocarbons, hydrocarbons, tetrahydrofuran, dimethylformamide or acetonitrile), base is added (for example triethylamine) followed by the appropriate sulfochloride.
• the reaction is carried out preferably between -10°C and ambient temperature.
• the reactions are followed by thin layer chromatography.
• the necessary reaction time is about 6-24 h.
• the work-up of the reaction mixture can be carried out by different methods.
• the products can be purified for example by crystallization or, if necessary, by column chromatography.
• the sulfochlorides of formula (II) are either commercially available or can be synthesized by different known methods, e.g. J.Chem.Soc, 1992, 4889-4898; J.Med.Chem., 1989, 32, 2436-2442; J.Med.Chem., 1993, 36, 320-330.
• the amines of formula (III) may be prepared by alkylation of compounds of formula (IV) or a derivative thereof
• the amines of formula (IV) are either commercially available or can be synthesized by different known methods: e.g. where X stands for CH and Y stands for NH group: Synlett, 1961, 537; where X stands for CH and Y stands for oxygen or OCH 2 : J.Med.Chem., 1974, 17, 1000; where X stands for CH and Y stands for CH 2 group: US 3,632,767; WO 97/23216; FR 2,534,580; where Y is a bond and X stands for nitrogen: Tetrahedron, 1999, 55, 13285-13300; J.Med.Chem., 1989, 32, 1052- 1056; US 2,922,788.
• the obtained derivatives of formula (I) can be transformed into an other compound of formula (I) in given case by introducing further substituent(s) and/or modifying and/or removing the existing one(s).
• cleaving the methyl group from a methoxy group which stands for Ri and/or R 2 and/or R 3 leads to phenol derivatives.
• the cleavage of methyl group can be carried out for example with boron tribromide in dichloromethane.
• the compounds of formula (I) containing cyano groups can be for example transformed to amides by hydrolysing them with hydrogenperoxide in dimethylsulfoxide, or to amidines by reacting them first with gaseous hydrogenchloride in ether, then by reacting the iminoester obtained with ammonia, etc.
• halogenation preferably bromination, of the terminal hydroxy group of a compound of formula (VII), wherein the meaning of R 6 is as described above for formula (VI), with a halogenation agent e.g.
• the invention also relates to the pharmaceutical compositions containing the compounds of formula (I) as active ingredient.
• the compounds of formula (I) of the present invention have been found to exhibit affinity for dopamine receptors, in particular the D 3 receptor, and are expected to be useful in the treatment of disease states which require modulation of such receptors, e.g. psychotic or ophthalmological disorders.
• the compounds of formula (I) have been found to have greater affinity for dopamine D 3 than for D 2 receptors.
• the compounds of formula (I) may therefore advantageously be used as selective modulators of D 3 receptors.
• Dysfunction of the dopaminergic neurotransmitter system is involved in the pathology of several neuropsychiatric disorders such as schizophrenia, Parkinson's disease and drug abuse.
• the effect of dopamine is mediated via at least five distinct dopamine receptors belonging to the D (D ⁇ D 5 ) or the D 2 - (D 2 , D 3 , D ) families.
• D 3 receptors have been shown to have characteristic distribution in the cerebral dopaminergic systems. Namely, high densities were found in certain limbic structures such as nucleus accumbens and islands of Calleja.
• D 3 receptors may be a promising approach for more selective modulation of dopaminergic functions and consequently for successful therapeutic intervention in several abnormalities, such as schizophrenia, emotional or cognitive dysfunctions and addiction (Sokoloff, P. et al: Nature, 1990, 347, 146; Schwartz, J.- C. et al.: Clin. Neuropharmacol., 1993, 16, 295; Levant, B.: Pharmacol. Rev., 1997, 49, 231.), addiction (Pilla, C. et al: Nature, 1999, 400, 371) and Parkinson's disease (Levant, B. et al.: CNS Drugs, 1999, 12, 391) or pain (Levant, B. et al.: Neurosci.
• Dopamine D 3 receptors are also implicated in regulation of intraocular pressure and agonists at these receptors are capable of decreasing the intraocular pressure (Chu, E. et al: J. Pharmacol. Exp. Ther., 2000, 292, 710), thus D 3 receptors agonists can be useful for the treatment of glaucoma.
• Certain compounds of formula (I) have been found to be dopamine D 3 receptor antagonist, others may be agonists or partial agonists.
• a further aspect of the present invention provides a method of treating conditions which require modulation of dopamine D 3 receptors, for example psychoses, for example in the treatment of schizophrenia, schizo-affective disorders, psychotic depression, mania, paranoid and delusional disorders, dyskinetic disorders such as Parkinson's disease, neuroleptic induced parkinsonism, depression, anxiety, memory disorders, sexual dysfunction, drug dependency and ophthalmological disorders which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a physiologically acceptable salt thereof.
• the invention also provides the use of a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof in the manufacture of a medicament for the treatment of conditions which require modulation of dopamine D 3 receptors.
• D 3 agonists or partial agonists according to the present invention is in the treatment of drug abuse (such as cocaine abuse etc.) and eye diseases (such as glaucoma).
• D 3 antagonists are in the treatment of schizophrenia, schizo-affective disorders, psychotic depression, mania, paranoid and delusional disorders, dyskinetic disorders such as Parkinson's disease, neuroleptic induced parkinsonism, depression, anxiety, memory disorders, sexual dysfunction, drug abuse, pain.
• the compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof are usually administered as a standard pharmaceutical composition.
• the present invention therefore provides in a further aspect pharmaceutical compositions comprising a new compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof and one or more physiologically acceptable carrier(s).
• the compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof may be administered by any convenient method, for example by oral, parental, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
• the compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof and the physiologically acceptable salts thereof which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
• a liquid formulation of the compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof generally consists of a suspension or solution of the compound of formula (I) or physiologically acceptable salts thereof in a suitable liquid carrier(s) for example an aqueous solvent, such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
• the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
• a composition in the solid form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, cellulose etc.
• a composition in the solid form of a capsule can be prepared using routine encapsulation procedures.
• pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatine capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatine capsule.
• Typical parenteral compositions consist of a solution or suspesion of the compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof or physiologically acceptable salt thereof in a steril aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
• the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
• compositions of the present invention for nasal administration containing a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof may conveniently be formulated as aerosols, drops, gels and powders.
• Aerosol formulations of the present invention typically comprise a solution or fine suspension of the compound of formula (I) in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in a single or multidose quantities in steril form is a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
• the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
• the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas, such as compressed air or an organic propellant, such as a fluorochlorohydrocarbon.
• the aerosol dosages form can also take the form af a pump-atomiser.
• compositions of the present invention containing a compound of formula (I) suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier, such as sugar and acacia, tragacanth, or gelatine and glycerin etc.
• compositions of the present invention containing a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof for rectal administration are conveniently in the form of suppositories containing a conventional supposiory base, such as cocoa butter.
• compositions of the present invention containing a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof for transdermal administration include ointments, gels and patches.
• compositions of the present invention containing a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof is preferably in the unit dose form, such as tablet, capsule or ampoule.
• Each dosage unit of the present invention for oral administration contains preferably from 1 to 250 mg of a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof calculated as a free base.
• Each dosage unit of the present invention for parenteral administration contains preferably from 0.1 to 25 mg of a compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof calculated as a free base.
• physiologically acceptable compounds formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof can normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose between 1 mg and 500 mg, preferably between 10 mg and 400 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g.
• the compound of the present invention can be administered 1 to 4 times per day.
• the compound of the present invention can suitably be administered for a period of continous therapy, for example for a week or more.
• Binding of [ 3 H]-spiperone (0.5 nM) to rat striatal tissue was measured according to the method of Seeman (J. Neurochem., 1984, 43 221-235). The nonspecific binding was determined in the presence of ( ⁇ )-sulpiride (10 ⁇ M).
• the most prominent side effects of the first generation antipsychotic compounds e.g. chlorpromazine and haloperidol
• preferential blockade at dopamine D 2 , and alpha-1 receptors are the tardive dyskinesia and orthostatic hypotension.
• the former one is the result of blockade of D 2 receptors in the basal ganglia whereas the latter is the consequence of antagonism of alpha-1 receptors.
• Compounds in Table 1 are potent ligands at D 3 receptors (IC-50 values are between 0.3 and 5.5 nM) and show 5 to 470 fold selectivity over D 2 receptors. Moreover, the compounds have beneficial profile in terms of potency on D 3 receptors and selectivity towards D 2 . It is therefore anticipated that no or greatly diminished adverse effects related to D 2 receptors will occur in the course of therapeutical application of compounds of the present invention.
• Example 1 7rans-(4- ⁇ 2-[4-(3-cyano-5-trifluoromethyl-phenyl)-piperazin-1-yl]-ethyl ⁇ - cyclohexyl)-carbamic acid fe/f-butyl ester
• Example 2 7rans-3- ⁇ 4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl ⁇ -5-trifluoromethyl- benzonitrile
• the mixture was filtered and the resin was washed in sequence with the following solvents (100 ml, twice with each): dichloromethane, methanol, 10% triethylamine in dimethylformamide, methanol, dimethylformamide, tetrahydrofuran, diethylether.
• the product was cleaved from the resin with shaking in 2 ml of 10% TFA in dichloromethane for two hours. The mixture was filtered and washed with the following solvents (10 ml, twice with each): dichloromethane, methanol, dichloromethane, and methanol. The filtrate was evaporated in vacuo to give the title product.
• the LC/MS analysis were performed using an HP 1100 binary gradient system, controlled by ChemStation software.
• Analytical chromatographic experiments were made on Discovery Ci 6 -Amide, 5 cm X 4.6 mm X 5 ⁇ m column with a flow rate of 1 ml/min for qualification (purity, capacity factor). All experiments were performed using HP MSD single quadruple mass spectrometer equipped with an electrospray ionisation source to determine the structure.
• Buffer suitable buffers include e.g. citrate, phosphate, sodium hydroxide/hydrochloric acid.
• Solvent typically water but may also include cyclodextrins (1 -100 mg) and co-solvents, such as propylene glycol, polyethylene glycol and alcohol.
• Disintegrant may also include cyclodextrins 5-50 mg
• Diluent e.g. mycrocrystalline cellulose, lactose starch.
• Binder e.g. polyvinylpyrrolidone, hydroxypropylmethylcellulose.
• Disintegrant e.g. sodium starch glycolate, crospovidone.
• Lubricant e.g. magnesium stearate, sodium stearyl fumarate d) Oral suspension
• Suspending agent e.g. xanthan gum, mycrocrystalline cellulose.
• Diluent e.g. sorbitol solution, typically water.
• Preservative e.g. sodium benzoate.
• Buffer e.g. citrate.
• Co-solvent e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• Ophthalmology & Optometry (AREA)
• Pain & Pain Management (AREA)
• Psychology (AREA)
• Hospice & Palliative Care (AREA)
• Addiction (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyridine Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=89979732

Family Applications (1)

Country Status (6)

Cited By (29)

Families Citing this family (13)

Citations (2)

Family Cites Families (10)

• 2001
  • 2001-09-28 HU HU0103988A patent/HU227543B1/hu unknown
• 2002
  • 2002-09-25 WO PCT/HU2002/000093 patent/WO2003029233A1/en not_active Ceased
  • 2002-09-25 PL PL370408A patent/PL210131B1/pl unknown
  • 2002-09-25 JP JP2003532483A patent/JP4250082B2/ja not_active Expired - Fee Related
  • 2002-09-25 US US10/491,150 patent/US7473692B2/en not_active Expired - Fee Related
  • 2002-09-25 EP EP02765129A patent/EP1438302B1/en not_active Expired - Lifetime

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events